Скачать с ютуб 肺癌治疗选择靶向治疗好还是免疫治疗好 金儿 浙江大学医学院附属杭州市第一人民医院 в хорошем качестве

肺癌治疗选择靶向治疗好还是免疫治疗好 金儿 浙江大学医学院附属杭州市第一人民医院

肺癌治疗选择靶向治疗好还是免疫治疗好 金儿 浙江大学医学院附属杭州市第一人民医院 肺癌的靶向治疗和免疫治疗都是很新的概念。免疫治疗也是一个非常新的治疗，免疫治疗与靶向治疗如何选择呢，首先如果是腺癌的话，肯定还是做基因检测，如果这个病人有EGFR基因阳性、ALK阳性、Ros-1阳性或HER-2基因阳性，首先是选择对应的靶向药物的，这个时候第一步是不选择免疫治疗的，因为有研究发现EGFR基因突变的病人，用免疫治疗的效果是不好的，所以只要测到了基因突变，还要使用靶向药物的。如果这些病人基因检测是阴性的，就是说没有靶点的突变，没有看到阳性的时候，这个时候是不是有机会选择免疫治疗，也是要做一个检测，主要通过PD-1、PD-L1的检测，如果这些表达有阳性的，尤其是大于50%的，现在认为是可以用免疫治疗或者是有些病人是不大于1%的，也可以用免疫治疗来做的，所以这两个药是这样来选择的。 Choice of target therapy or immunotherapy for lung cancer Targeted therapy and immunotherapy for lung cancer are new concepts. Immunotherapy is also a very new treatment, How to choose immunotherapy and targeted therapy, First of all, if it's adenocarcinoma, It's still a genetic test, If the patient is EGFR, ALK, ros-1 or HER-2 positive, The first is to select the corresponding targeted drugs, The first step is not to choose immunotherapy, Because some studies have found that EGFR gene mutations in patients, The effect of immunotherapy is not good, So as long as the mutation is detected, And target drugs. If these patients have negative genetic tests, That is to say, there is no target mutation, When you don't see positive, Is there a chance to choose immunotherapy at this time, It's also a test, It mainly passes the detection of PD-1 and PD-L1, If these expressions are positive, Especially those over 50%, Now it is believed that immunotherapy can be used or that some patients are no more than 1%, It can also be done with immunotherapy, So these two drugs are chosen in this way.